Latest / Vertical SaaS with Fexingo: Industry-Specific Software for Healthcare, Construction, Legal / How Vertical SaaS Is Unifying Independent Pharmacy Networks
Transcript
- Lucas: So there's this statistic that's been stuck in my head for a while. Independent pharmacies — the ones not owned by CVS, Walgreens, or a hospital system — fill about 40 percent of all retail prescriptions in the U.S. That's roughly 1.5 billion prescriptions a year going through stores that are often run by a single pharmacist-owner. Luna: Forty percent — that's way higher than I expected. I always assume the big chains had the vast majority. Lucas: Right, and that's partly because the big chains are so visible. But the independents exist in that number because they offer things the chains often don't: personalized service, home delivery, compounding, longer hours. The problem is, they're fighting with one hand tied behind their back on the tech side. Luna: What does that look like practically? I mean, they have to fill prescriptions — that's not something you can do with pen and paper. Lucas: They have software — most of them have been using some kind of pharmacy management system since the 90s. But those systems were essentially electronic filing cabinets. They handled the prescription label, the billing, a basic patient profile. What they didn't do is connect pharmacies to each other or give them any kind of collective bargaining power. Lucas: That's where the vertical SaaS story gets interesting. A company called PioneerRx — based in Shreveport, Louisiana — started building a modern cloud-based pharmacy management platform about 15 years ago. They now have over 6,500 independent pharmacies on their system. Luna: Six thousand five hundred — that's a significant chunk of the roughly 20,000 independent pharmacies in the U.S. What makes their platform different from the old systems? Lucas: The core functionality is the same in one sense — you need to process a prescription, check for drug interactions, submit the claim to the insurance plan, and generate a label. PioneerRx does all that, but it does it in the cloud with a modern interface. The big leap is that because it's cloud-native, data from all those pharmacies can be aggregated. Lucas: So the platform knows, across its entire network, which drugs are in short supply, which generics have the best reimbursement rates, which plans are slow to pay. That data becomes a strategic asset. Luna: That sounds like classic network effects — the more pharmacies join, the more valuable the data becomes. But how does that translate into actual dollars for the pharmacy owner? Lucas: The most direct lever is group purchasing. Individually, a pharmacy buying a hundred bottles of a generic drug has very little negotiating power. But when PioneerRx aggregates the purchasing of 6,500 pharmacies — that's buying power. They've negotiated deals with wholesalers that can reduce the cost of goods sold by 2 to 4 percent. Luna: On a pharmacy's typical margin — what is that, like 3 percent? — a 2 percent reduction in cost of goods is huge. That's almost doubling your margin. Lucas: Exactly. The average independent pharmacy operates on a net margin of about 3 to 4 percent. So even a 50-basis-point improvement is meaningful. And the group purchasing benefit alone can deliver that. But there are other features too: automated inventory management that reduces waste, integrated marketing tools that let a pharmacy send refill reminders or health fair announcements, and even a shared formulary database. Luna: Let's talk about the elephant in the room: pharmacy benefit managers — PBMs. That's where a lot of the margin pressure comes from, right? Lucas: Yeah, PBMs are the intermediaries that manage prescription drug plans for insurers and employers. They set reimbursement rates, and they've been known to squeeze independents — sometimes reimbursing below cost for certain drugs. PioneerRx has built tools that help pharmacies understand their reimbursement contracts and flag when a claim is being underpaid. Lucas: And because the platform has data from thousands of pharmacies, it can identify patterns — like a particular PBM that is consistently late on payments or a specific plan that reimburses below the national average. That gives the pharmacy owner leverage when they negotiate. Luna: It's almost like the software is giving them the ammunition they need to fight a data war. The big chains have their own massive data sets and analytics teams. The independents, historically, have had nothing. Lucas: And that's the vertical SaaS promise in a nutshell. You take an underserved industry, you build software that handles the core workflow, and then you layer on network effects that make each customer stronger by being part of the collective. The pharmacy example is particularly clean because the economics are so tight — every basis point matters. Lucas: I think what's also interesting is that PioneerRx isn't the only player. There's also Computer-Rx, QS/1, and a few others. But PioneerRx has been winning on product design — they have a much more modern interface — and on the network strategy. Luna: Are there any downsides? I mean, if you're a small pharmacy, you're essentially tying your business to this one software vendor. What happens if they raise prices or get acquired by a private equity firm that changes the terms? Lucas: That's a real risk. Switching costs in pharmacy management software are high because you have years of patient data, prescription histories, billing codes — migrating that is a nightmare. Some pharmacies have been burned by vendors that were acquired and then changed their pricing model. But the alternative — staying on a system that doesn't give you group purchasing or analytics — is arguably worse. Lucas: And it's worth noting that PioneerRx is still privately held by its founders, which gives them more freedom to focus on the product rather than quarterly earnings. But that could change. Luna: Hey Lucas, this kind of deep dive into the mechanics of an industry — understanding how margins work, how technology shifts the balance of power — that's exactly why I love doing this show. And it's why a lot of listeners tell me they appreciate that we keep it ad-free. If you're finding these conversations useful for what you're building or running, you can support the show at buy me a coffee dot com slash fexingo. It's what keeps us going without any sponsors. Lucas: Yeah, Luna, I think that's a fair point. And we genuinely appreciate every person who chips in. It lets us spend the time to find these specific cases rather than just doing surface-level takes. Luna: Alright, back to the pharmacy. You mentioned PioneerRx has 6,500 pharmacies — what's the growth trajectory? Are they adding hundreds a year? Lucas: They've been adding roughly 500 to 600 pharmacies per year for the last few years. And the interesting thing is that the value proposition actually gets stronger as the network grows. More pharmacies mean better data on drug pricing, more leverage with wholesalers, and a richer formulary database. So the growth should compound. Luna: That's the network effect I mentioned earlier. But is there any risk that the big chains start offering similar group purchasing or data tools to independents to pull them away? Lucas: That's a real threat, but it's not easy. The big chains' software is built for their own store operations, not for independent owners. And they compete directly with the independents, so there's a trust issue. Would you hand your patient data and purchasing decisions to CVS if you're trying to compete with CVS? Probably not. Luna: Right, that would be like a small retailer using Walmart's supply chain software. It doesn't make sense. Lucas: Exactly. So the independent pharmacy vertical is actually a pretty defensible space for a vertical SaaS company. The barriers to entry include not just the software itself, but the relationships with wholesalers, the data network effects, and the trust of the pharmacy owners. Lucas: There's another angle I want to touch on: compliance. Pharmacies are heavily regulated — state boards, DEA, HIPAA for patient data. PioneerRx has built features that help pharmacies stay compliant, like automated reporting for controlled substances and audit trails for patient records. That reduces the administrative burden and the risk of fines. Luna: So the software is essentially acting as a compliance officer, a purchasing agent, and a marketing department all in one. That's a lot of value for a monthly subscription that probably runs a few hundred dollars. Lucas: Yeah, typical pricing for a pharmacy management system is in the range of $300 to $600 a month for the core platform, plus transaction fees or add-on modules. For a pharmacy doing, say, $3 million a year in revenue, that's less than 0.2 percent of revenue. If the software helps cut costs by even 1 percent, it pays for itself many times over. Luna: That's the kind of ROI that makes it a no-brainer. But I'm curious — is this model replicable in other healthcare verticals? Like dental or vet, which we've covered before? Lucas: The playbook is similar, but each vertical has its own quirks. In dental, the insurance reimbursement structure is different, and the lab workflow for crowns and dentures is unique. In vet, the drug dispensing is similar but the patient records are for animals, not humans, so the regulatory environment is lighter. But the core idea — build the workflow software, then add network effects — works across many industries. Lucas: For episode 100, I think the pharmacy vertical is a great example of why vertical SaaS matters. It's not just about digitizing a paper process. It's about rebalancing power in an industry where the small players were getting squeezed. Luna: And it's a reminder that the best technology stories aren't always about the flashiest AI — sometimes it's about giving a pharmacist in a small town the same data leverage as a Fortune 500 company. Lucas: Well said. That's all for this episode of Vertical SaaS with Fexingo. We'll be back next time with another deep dive into how software is reshaping a specific industry.